2025-04-22
Functional Cure for Hepatitis B: Mechanistic Insights, Emerging Therapeutics, and AbinScience Research‑Grade Tools
Hepatitis B Virus (HBV) impacts over 254 million people worldwide, posing a major challenge due to its species-specific nature and lack of immunocompetent preclinical models. Its persistence, driven by covalently closed circular DNA (cccDNA), complicates curative efforts. This article explores HBV’s infection mechanisms, limitations of current treatments like nucleos(t)ide analogs, and emerging strategies such as CRISPR-based gene editing, RNA interference, and viral entry inhibition. AbinScience supports HBV research by offering research-grade biologics, enabling studies into viral entry, replication, and antigen expression to advance therapeutic development for a future free of HBV.
